Samsung Bioepis Bevacizumab Nod Sets Stage For EU Throwdown
Aybintio Joins Amgen And Pfizer Avastin Rivals Ready For Expiry
Executive Summary
Samsung Bioepis has received a pan-European endorsement from the CHMP for its Aybintio bevacizumab biosimilar. The nod follows two previous European Avastin biosimilar approvals, with market formation believed to be imminent.
You may also be interested in...
Samsung Bioepis Receives EU Bevacizumab Approval
With the European Commission’s approval of Aybintio (bevacizumab), Samsung Bioepis now has five approved biosimilars for Europe.
What’s Next? Five Things To Look Out For In August
Second-quarter earnings results from two of the Big Three – Teva and Mylan – hold much of the intrigue in August, while more competition in the nascent Avastin biosimilar market could materialize in Europe.
Updated: Multiple Biosimilars To Avastin Have Launched In EU
Roche’s biggest seller, Avastin, has fallen to biosimilar competition in Europe, with at least one company confirming launch to Generics Bulletin.